Reata Pharmaceuticals, Inc. The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Eastern District of Texas on behalf of shareholders of Reata Pharmaceuticals, Inc. who purchased securities and/or put options between November 9, 2020 and December 8, 2021.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) as a result, there was a material risk that Reata’s New Drug Application would not be approved; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
“Reata Pharmaceuticals, Inc.”
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until February 18, 2022 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
